In:
Interface Focus, The Royal Society, Vol. 9, No. 2 ( 2019-04-06), p. 20180077-
Abstract:
The initial part of this review details the controversy behind the use of a serological level of prostate-specific antigen (PSA) for the diagnostics of prostate cancer (PCa). Novel biomarkers are in demand for PCa diagnostics, outperforming traditional PSA tests. The review provides a detailed and comprehensive summary that PSA glycoprofiling can effectively solve this problem, thereby considerably reducing the number of unnecessary biopsies. In addition, PSA glycoprofiling can serve as a prognostic PCa biomarker to identify PCa patients with an aggressive form of PCa, avoiding unnecessary further treatments which are significantly life altering (incontinence or impotence).
Type of Medium:
Online Resource
ISSN:
2042-8898
,
2042-8901
DOI:
10.1098/rsfs.2018.0077
Language:
English
Publisher:
The Royal Society
Publication Date:
2019
detail.hit.zdb_id:
2585655-8
Permalink